此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

SPECTATOR: Perfusion Monitoring Before, During and After Lower Extremity Revascularization With Laser Speckle Contrast Imaging (SPECTATOR)

2026年9月17日 更新者:Joost R. van der Vorst, MD, PhD、Leiden University Medical Center

This study aims to evaluate the feasibility of Laser Speckle Contrast Imaging for perioperative perfusion assessment of the lower extremity before, during, and after revascularization.

研究概览

详细说明

Rationale: Lower extremity arterial disease (LEAD) arises from atherosclerotic obstruction in the lower limbs, which in turn leads to symptoms ranging from intermittent claudication to ulcer formation. As the disease progresses, patients often require revascularization to achieve limb salvage.

To improve prediction of clinical outcomes following revascularization, various techniques have been introduced to quantify tissue perfusion. Among these, near-infrared fluorescence imaging with indocyanine green (ICG NIRF) has gained attention. This method combines a laser light source with intravenous ICG administration to visualize perfusion. Although ICG NIRF appears promising for guiding revascularization strategies and predicting outcomes, its invasive nature, requiring dye injection, limits its use in outpatient settings.

Consequently, there is a need for a non-invasive, real-time technique that enables rapid and straightforward perfusion assessment. One such promising approach is laser speckle contrast imaging (LSCI). Therefore, this study aims to evaluate the feasibility of LSCI for perioperative perfusion assessment of the lower extremity before, during, and after revascularization.

Objective:The primary objective of this study is to evaluate the feasibility of laser speckle contrast imaging (LSCI) for monitoring perfusion in the lower extremities during and following revascularization.

Secondary objectives include correlating LSCI findings with the temperature of the patient's foot, comparing LSCI with near-infrared fluorescence imaging using indocyanine green (ICG NIRF) and exploring potential quantitative approaches such as the assessment of blood flow pulsatility.

Study design: This study will be a prospective cohort study. Study population: Adult patients undergoing a revascularization of the lower extremity due to peripheral artery disease. Such revascularization can be bypass surgery, thrombo-endarterectomy (TEA), or endovascular percutaneous transluminal angioplasty (PTA).

Intervention: Patients will undergo peri-operative and post-operative LSCI.

Main study parameters/endpoints: The main study parameters are the quantified perfusion parameters measured with LSCI.

Nature and extent of the burden and risks associated with participation. The use of the LSCI device is not expected to cause any adverse effects, as it employs a low-intensity near-infrared laser to illuminate the skin. The photon energy and illumination power used are well below levels that could cause tissue damage and are therefore considered safe for human skin. All measurements are performed alongside standard assessments or routine outpatient clinic appointments. The intraoperative measurement does not extend the duration of the surgical procedure. Given the short duration of each measurement (5-10 seconds), no additional burden on patients is anticipated.

研究类型

观察性的

注册 (估计的)

30

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • South Holland
      • Leiden、South Holland、荷兰、2333ZA
        • 招聘中
        • Leiden University Medical Center
        • 接触:
        • 接触:
        • 副研究员:
          • Indy Planting, MD
        • 首席研究员:
          • Joost van der Vorst, PhD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

概率样本

研究人群

The population of this study will undergo a revascularization of the lower extremity due to peripheral artery disease. Such revascularization can be bypass surgery, thrombo-endarterectomy (TEA), or endovascular percutaneous transluminal angioplasty (PTA).

描述

Inclusion Criteria:

  • Scheduled for lower-extremity revascularization
  • Undergoing pre- and postoperative indocyanine near-infrared fluorescence perfusion measurements

Exclusion Criteria:

Any condition that the investigator considers to be potentially jeopardizing the patient's wellbeing or the study objectives

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Fontaine 2

Measurement with LSCI device

Fontaine 3

Measurement with LSCI device

Fontaine 4

Measurement with LSCI device

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
To assess the feasibility and the quantification of laser speckle contrast imaging for monitoring of perfusion of the lower extremities during and following revascularization
大体时间:Up to 48 hours (from pre-operative baseline measurement to the final postoperative measurement, performed on the same day for PTA procedures or on postoperative day 1 for bypass and TEA procedures)

Feasibility

Up to 48 hours (from pre-operative baseline measurement to the final postoperative measurement, performed on the same day for PTA procedures or on postoperative day 1 for bypass and TEA procedures)

次要结果测量

结果测量
措施说明
大体时间
Correlation of pre-, intra- and postsurgery laser speckle contrast imaging (LSCI) findings with the pre-, intra- and post-temperature of the patient's foot
大体时间:Up to 48 hours (from pre-operative baseline measurement to the final postoperative measurement, performed on the same day for PTA procedures or on postoperative day 1 for bypass and TEA procedures)

Temperature

Up to 48 hours (from pre-operative baseline measurement to the final postoperative measurement, performed on the same day for PTA procedures or on postoperative day 1 for bypass and TEA procedures)
Comparative analysis of LSCI with standard of care near-infrared fluorescence imaging using ICG
大体时间:Up to 48 hours (from pre-operative baseline measurement to the final postoperative measurement, performed on the same day for PTA procedures or on postoperative day 1 for bypass and TEA procedures)

ICG

Up to 48 hours (from pre-operative baseline measurement to the final postoperative measurement, performed on the same day for PTA procedures or on postoperative day 1 for bypass and TEA procedures)
Clinical outcomes
大体时间:Clinical outcome data (wound healing, limb salvage, complications) extracted from routine postoperative follow-up assessments, up to 6 weeks after revascularization; no additional study-specific measurements are performed at this follow-up visit

Correlation of quantified LSCI recordings to clinical outcomes

Clinical outcome data (wound healing, limb salvage, complications) extracted from routine postoperative follow-up assessments, up to 6 weeks after revascularization; no additional study-specific measurements are performed at this follow-up visit
Effect of anesthesia induction on quantified LSCI perfusion values
大体时间:Pre-anesthesia induction and within 15 minutes post-anesthesia induction

Exploratory comparison of quantified laser speckle perfusion units (LSPU) in the plantar region of interest measured before versus within 15 minutes after induction of anesthesia (prior to revascularization), to assess whether anesthesia induction is associated with a change in LSCI-derived perfusion values. Measurement setup and non-invasive LSCI acquisition procedure are unchanged from the pre-anesthesia measurement; no additional burden or risk to participants.

Pre-anesthesia induction and within 15 minutes post-anesthesia induction
Exploratory assessment of blood flow pulsatility using LSCI
大体时间:Intraoperative, during the reperfusion phase (in the subset of participants undergoing TEA or PTA procedures with intraoperative regional oximetry monitoring)

Exploratory, opportunistic analysis performed only in the subset of participants for whom intraoperative INVOS regional oximetry data are available as part of standard care; not assessed in all participants

Intraoperative, during the reperfusion phase (in the subset of participants undergoing TEA or PTA procedures with intraoperative regional oximetry monitoring)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月1日

初级完成 (估计的)

2028年5月1日

研究完成 (估计的)

2028年6月1日

研究注册日期

首次提交

2026年4月23日

首先提交符合 QC 标准的

2026年4月23日

首次发布 (实际的)

2026年4月30日

研究记录更新

最后更新发布 (实际的)

2026年9月23日

上次提交的符合 QC 标准的更新

2026年9月17日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅